ATR Q1 2026 Earnings Call Summary

Summary of Aptar's Q1 2026 Earnings Call

1. Key Financial Results and Metrics

Sales Growth: Reported sales increased by 11%, while core sales (adjusted for currency and acquisitions) were flat year-over-year.
Adjusted EBITDA: Reached $189 million, up 3% from the previous year, with an adjusted EBITDA margin of 19.2%, down from 20.7% in Q1 2025.
Adjusted Earnings Per Share (EPS): Reported at $1.19, compared to $1.30 in the prior year, reflecting an 8% decline at comparable exchange rates.
Free Cash Flow: More than doubled to $53 million, with cash from operations at $119 million after capital expenditures of $65 million.
Balance Sheet: Ended the quarter with a cash balance of $223 million, net debt of $1.1 billion, and a leverage ratio of 1.43.

2. Strategic Updates and Business Highlights

Pharma Segment: Continued demand in GLP-1 biologics, systemic nasal drug delivery, and ophthalmic dispensing. However, core sales decreased by 1%, primarily due to a decline in emergency medicine sales.
Consumer Healthcare: Core sales increased by 4%, driven by eye care and nasal decongestant products.
Beauty Segment: Core sales rose by 3%, with notable growth in prestige fragrances and color cosmetics.
Closures Segment: Core sales were flat, impacted by lower resin pricing, though beverage sales increased by 10%.
Product Launches: New products launched in both Pharma and Beauty, including advancements in nasal drug delivery and innovative dispensing technologies.

3. Forward Guidance and Outlook

Q2 2026 Guidance: Anticipated adjusted EPS in the range of $1.32 to $1.40. Expect continued growth across segments, particularly in Pharma (excluding emergency medicine) and Beauty.
Full-Year 2026 Outlook: Capital investments projected between $260 million and $280 million, with depreciation and amortization expected to be $310 million to $320 million.

4. Bad News, Challenges, or Points of Concern

Emergency Medicine Decline: Anticipated decline of approximately $65 million in emergency medicine sales for the full year, with a 3% negative impact on core sales in Q1.
Margin Compression: Adjusted EBITDA margin decreased due to unfavorable product mix and operational challenges, particularly in Beauty and Closures.
Operational Issues: Maintenance challenges and extreme weather conditions impacted production, particularly in the Closures segment.
Litigation: Ongoing litigation with ARS Pharmaceuticals, with no significant updates available during the call.

5. Notable Q&A Insights

Pharma Growth Expectations: Management expressed confidence in solid growth for the Pharma segment in Q2, excluding emergency medicine impacts.
GLP-1 Capacity: Confirmed sufficient capacity in elastomeric components for GLP-1 biologics, with no immediate plans for additional capacity expansion.
Supply Chain Management: Increased safety stock of raw materials to mitigate potential supply chain disruptions due to rising costs and geopolitical tensions.
Market Dynamics: Management noted that while emergency medicine sales may not see the same level of demand as in previous quarters, they expect a more stable market moving forward.

Overall, while Aptar faced challenges in specific segments, particularly related to emergency medicine, the company remains optimistic about growth in other areas and is actively managing operational and supply chain issues.

ATR — AptarGroup, Inc.